India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Financial analysis remains one of the strongest career paths for professionals seeking high earnings, steady growth, and long-term stability. With median salaries above $100K, expanding demand across industries, and clear promotion tracks leading to senior leadership roles, the field offers both opportunity and resilience—even as AI reshapes the workplace. This article breaks down what analysts do, salary expectations, job outlook, industry demand, and whether this career is the right fit for you.
After losing their home in the Los Angeles wildfires, Jessica and Matt Conkle expected their insurance policy to help them rebuild. Instead, they found themselves trapped in delays, lowball offers, and endless adjuster changes — a struggle now shared by thousands across California. Their experience highlights a nationwide problem: insurers pulling back from climate‑risk areas, soaring premiums, shrinking coverage, and regulators under fire. For professionals in real estate, mortgage, and insurance, this growing instability is reshaping transactions, lending, risk assessment, and the future of homeownership in America.
Kansas City’s housing market is finally gaining momentum heading into 2026 as falling interest rates, new construction, and a renewed focus on affordable homes open the door for first‑time buyers. Economists say improved supply and softer mortgage rates could shift the market after a challenging 2025, giving real estate professionals and buyers a promising window of opportunity.
Nevada has become the first state to allow insurers to sell homeowners policies without wildfire protection—a move aimed at lowering premiums but raising concerns about consumer risk and mortgage barriers. The law introduces new wildfire‑only policies and a regulatory sandbox for insurance innovation, potentially setting a precedent for other Western states.
Investment groups across the U.S. are rapidly expanding into tax‑deferred real estate programs as demand for Delaware Statutory Trusts (DSTs) accelerates. Major players like Blackstone, Brookfield, Denholtz, and PREP are launching new offerings fueled by stronger market certainty, a historic generational wealth transfer, and renewed confidence in 1031 exchange benefits. As DSTs move into the mainstream, real estate professionals are finding new opportunities to guide clients through advanced tax‑advantaged investment strategies.
Canada’s proptech sector is evolving fast as AI adoption accelerates and investor caution forces startups to mature. Funding has tightened, growth rounds have slowed, and companies are shifting from rapid expansion to profitability and real product‑market fit. AI‑driven platforms like Mave are gaining traction, consolidation is rising, and government housing initiatives may boost construction‑focused tech. For real estate professionals, these trends signal a new industry standard where AI tools and ongoing education are essential to staying competitive.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
